secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001558370-25-008430
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris shareholders approve doubling authorized shares to 400M and new equity plan with 25.6M reserve
--------------------------------------------------------------------------------

- Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.
- 2025 Equity Incentive Plan approved with 25,556,247 share reserve (9M new shares plus rollover from prior plan).
- Directors elected: Neal Walker (71.9M for), Andrew Schiff (71.7M for), William Humphries (56.7M for, 15.99M withheld).
- Advisory vote on named executive officer compensation passed 55.5M to 16.98M; PwC ratified as auditor for FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025008430/0001558370-25-008430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025008430/acrs-20250605x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer